COMPANY PROFILE

T3 Pharmaceuticals

Explore full profile

Biotech company specialising in bacteria based cancer therapies

Basel, SwitzerlandFounded 2015Biotech & Life Sciences

Valuation $250–500M Last recorded · 2023

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About T3 Pharmaceuticals

T3 Pharmaceuticals is a pre-clinical biopharmaceutical company focused on developing next-generation bacterial cancer therapies. The company leverages live bacteria to deliver highly specific and efficient treatments aimed at improving the lives of cancer patients. Founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz, and Helmut Kessmann, T3 Pharmaceuticals operates in the oncology market, targeting unmet needs in cancer treatment. The business model revolves around research and development, with a focus on creating innovative therapies that can be commercialized through partnerships or direct sales. Revenue is generated through licensing agreements, research grants, and potential future sales of approved therapies. The company serves healthcare providers, research institutions, and ultimately cancer patients who require novel treatment options.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2015
Headquarters: Basel, Switzerland
Employees: 30
Open positions: None listed
Dealroom signal: 81.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Activities, Bacteria, Spinout, Alternative Protein, Macro-Nutrients, Biotech and Pharma, Hard Tech, Woman Founder
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Nov 2023	$413M	$413M	Boehringer Ingelheim	↗
GRANTOther financing	Apr 2023	$0	—	Innosuisse	↗

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

T3 Pharmaceuticals website traffic

Latest recorded traffic for T3 Pharmaceuticals is 120 monthly website visits, down 64.7% over the last three months. T3 Pharmaceuticals's team grew 20% over the past year.

Latest monthly visits120 3-month web change-64.7% 1-year team growth+20%

Monthly website visitsJan 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational	10	$616K	$2.5M
HOHolloidProvides real-time multi-dimensional data on colloids, based on 3D imaging, with the throughput of cytometry	Vienna, Austria	Operational
OMOnena MedicinesRevolutionary AI-optimized medicines delivering hope where it’s needed most	Allschwil, Switzerland	Operational
SPSpireaAdvanced antibody-drug conjugate technology for cancer therapeutics	Harrogate, United Kingdom	Operational
CECellmAbsCellmabs is focused on researching and developing innovative biopharmaceuticals for the treatment of cancer	Óbidos, Portugal	Acquired
VTValo TherapeuticsAn immunooncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines	Helsinki, Finland	Operational
INInvasightA clinical biotech company that focused on revolutionizing cell invasion research	Zurich, Switzerland	Operational
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational